ANTX
NASDAQAN2 Therapeutics Inc.
News · 26 weeks37-56%
2026-04-192026-10-11
Mix1890d
- Insider10(56%)
- Other4(22%)
- SEC Filings3(17%)
- Leadership1(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by AN2 Therapeutics Inc.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by AN2 Therapeutics Inc.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERSEC Form 4 filed by AN2 Therapeutics Inc.4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- PRAN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSKFunding from Gates Foundation supports continued advancement of boron-based LeuRS inhibitors for the treatment of tuberculosis AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS) inhibitors. TB remains a major global public health challenge. Globally, TB is the world’s leading cause of
- INSIDERChief Medical Officer Trenor Cameron C. Iii was granted 116,667 shares (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- PRAN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor, M.D., the Company’s newly-appointed Chief Medical Officer.The inducement awards consist of a non-qualified stock option to purchase 233,333 shares of the Company’s common stock and restricted stock units representing 116,667 shares of the Company’s common stock. The option has an exercise price of $5.36 per share, which is equal to the closing price of the Company’s common stock on the date of grant. The option has a 10-year term and will vest over four ye
- SECSEC Form S-8 filed by AN2 Therapeutics Inc.S-8 - AN2 Therapeutics, Inc. (0001880438) (Filer)
- INSIDERDirector Readnour Robin Shane sold $6,675 worth of shares (1,108 units at $6.02) as part of a pre-agreed trading plan (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERDirector Readnour Robin Shane sold $97,323 worth of shares (16,119 units at $6.04) as part of a pre-agreed trading plan (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERDirector Fitzpatrick Margaret M bought $11,602 worth of shares (2,098 units at $5.53), increasing direct ownership by 24% to 10,708 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- PRAN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingAbstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Cent
- INSIDERSEC Form 3 filed by new insider Trenor Cameron C. Iii3 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- PRAN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical OfficerDr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the appointment of Cameron Trenor, M.D., as Chief Medical Officer. Dr. Trenor is an accomplished physician-scientist and biotechnology executive with more than 20 years of experience leading clinical and translational development programs across hematology, rare diseases, oncology, immunology and metabolic disorders. He h
- INSIDERDirector Readnour Robin Shane sold $212,702 worth of shares (35,402 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERDirector Zakrzewski Joseph S gifted 405,880 shares (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SECSEC Form 10-Q filed by AN2 Therapeutics Inc.10-Q - AN2 Therapeutics, Inc. (0001880438) (Filer)
- SECAN2 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
- PRAN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific HighlightsExpanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Positive non-human primate efficacy and favorable Phase 1 clinical pharmacokinetics and safety profile support planned Phase 2 initiation of AN2-502998 in chronic Chagas disease by year-end Plan to advance second boron-based compound into development in 2026 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported
- INSIDERDirector Aziz Kabeer was granted 2,852 shares, increasing direct ownership by 5% to 59,106 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERDirector Marks Gilbert Lynn was granted 2,789 shares, increasing direct ownership by 4% to 81,873 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDERDirector Martin Patricia A. was granted 766 shares, increasing direct ownership by 4% to 18,863 units (SEC Form 4)4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- INSIDEROfficer Eizen Joshua M sold $24,803 worth of shares (5,945 units at $4.17), decreasing direct ownership by 3% to 206,554 units (SEC Form 4) to satisfy tax liability4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
- SECAN2 Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
- PRAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas DiseaseParasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval AN2 Therapeutics, Inc. (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company's oral CPSF3 inhibitor, AN2-502998, for the treatment of ch
- INSIDERPrincipal Accounting Officer Williams Sarah Joanne sold $1,174 worth of shares (265 units at $4.43), decreasing direct ownership by 0.40% to 66,583 units (SEC Form 4) to satisfy withholding obligation4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)
ANTX FAQ
7 questionsWhat does AN2 Therapeutics Inc. do?
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.Where does ANTX stock trade?
AN2 Therapeutics Inc. (ANTX) is listed on NASDAQ.What sector and industry is ANTX in?
AN2 Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AN2 Therapeutics Inc. go public?
AN2 Therapeutics Inc. (ANTX) completed its IPO in 2022.What are analysts saying about ANTX?
AN2 Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $900.00 price target on 2026-05-14.What companies are similar to ANTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ANTX side-by-side with any of them on Quantisnow.How can I track ANTX on Quantisnow?
Quantisnow aggregates AN2 Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANTX to receive live email and push alerts on every new disclosure.